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Background: The outcome of patients with metastatic colorectal carcinoma (mCRC) following first line therapy is
poor, with median survival of less than one year. The purpose of this study was to identify candidate therapeutically
targetable somatic events in mCRC patient samples by whole genome sequencing (WGS), so as to obtain targeted
treatment strategies for individual patients.
Methods: Four patients were recruited, all of whom had received > 2 prior therapy regimens. Percutaneous needle
biopsies of metastases were performed with whole blood collection for the extraction of constitutional DNA. One
tumor was not included in this study as the quality of tumor tissue was not sufficient for further analysis. WGS was
performed using Illumina paired end chemistry on HiSeq2000 sequencing systems, which yielded coverage of
greater than 30X for all samples. NGS data were processed and analyzed to detect somatic genomic alterations
including point mutations, indels, copy number alterations, translocations and rearrangements.
Results: All 3 tumor samples had KRAS mutations, while 2 tumors contained mutations in the APC gene and the
PIK3CA gene. Although we did not identify a TCF7L2-VTI1A translocation, we did detect a TCF7L2 mutation in one
tumor. Among the other interesting mutated genes was INPPL1, an important gene involved in PI3 kinase signaling.
Functional studies demonstrated that inhibition of INPPL1 reduced growth of CRC cells, suggesting that INPPL1 may
promote growth in CRC.
Conclusions: Our study further supports potential molecularly defined therapeutic contexts that might provide
insights into treatment strategies for refractory mCRC. New insights into the role of INPPL1 in colon tumor cell
growth have also been identified. Continued development of appropriate targeted agents towards specific events
may be warranted to help improve outcomes in CRC.
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Colorectal cancer (CRC) is one of the most common
cancers in the United States with an estimated 150,000
new cases and 50,000 deaths each year [1]. While early
stage CRC (stage I and II) has a high cure rate after sur-
gery, the recurrence rate is about 50% for stage III CRC
after surgery alone and most patients with metastatic* Correspondence: jcarpten@tgen.org
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distribution, and reproduction in any mediumdisease will ultimately succumb to their cancer [2].
Chemotherapy is the primary treatment for metastatic
disease. Currently, there are roughly 5 classes of approved
drugs for treating mCRC [3]. These agents include: (1)
Fluoropyrimidines: 5-FU and capecitabine (2) Platinum
derivative: oxaliplatin (3) Camptothecin derivative: irinotecan
(4) EGFR inhibitors: cetuximab and panitumumab and (5)
VEGF inhibitors: bevacizumab, afibercept and regorafenib.
EGFR inhibitors represent “targeted agents” and their use
is limited to about 60% of tumors, which have wild type
KRAS genotype. These agents are given in combination,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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of treatment options after 2–3 lines of therapy, with a
commonly used sequence being a combination of 5-FU,
oxaliplatin and bevacizumab (FOLFOX + bevacizumab)
followed by 5-FU/irinotecan (FOLFIRI) with the addition of
bevacizumab or afibercept, and the recently approved agent,
regorafenib as a third line option in some patients [4].
A number of molecular targets and pathways have been
described in CRC. Aberrations in chromosome instability
and mismatch repair have been widely identified in a
number of cases (85%) [5] with mutations in APC and
MutL-homolog (MLH) genes. Mutations in TP53 have
been found in about 50% of colorectal cancers globally
[6] as p53 plays key roles in cell regulation, apoptosis,
DNA repair and differentiation. KRAS mutations are also
common in CRC, and occur at a frequency of ~ 40% [7].
Several other pathways which also trigger the malignant
phenotype include the TGFβ signaling pathway mediated
through downstream targets such as SMAD2 and SMAD4,
and components of RAS/MAPK, JNK and PI3K/AKT path-
ways [8]. Studies of protein coding genomic sequences of
colorectal cancers revealed that only a subset of these genes
actually contribute to the process of carcinogenesis whereas
a vast majority of them actually affect other cellular pro-
cesses such as transcription, adhesion and invasion [9]. Se-
quencing studies of the mutational landscape of colorectal
cancer revealed that the mutational spectrum is comprised
of a limited number of frequently mutated genes and a
large number of infrequently mutated genes [10]. Fur-
thermore, a previous sequencing study of 9 colorectal
cancers and matched normal tissues reported additional
recurrent events, notably a VTI1A-TCF7L2 fusion gene
present in ~ 3% of the patients [11].
Personalized CRC patient treatment based on character-
izing the individual tumors by high throughput sequencing
strategies has been attempted [12]. Most studies reporting
sequencing data have been with panels of select genes,
or with cell lines, patient derived xenografts, or primary
tumors removed at surgery [13]. Our group has instituted
a pilot program to sequence various solid tumors in pa-
tients with refractory solid tumors [14,15]. In obtaining
clinically relevant information that can be of use by the
treating physician, tumor biopsies are obtained in patients
with advanced solid tumors refractory to approved therap-
ies [16,17]. In our current study, we utilized next gener-
ation sequencing technologies (NGS) to identify potential




All patients signed an IRB approved consent form
prior to participation at the Virginia G. Piper Cancer
Center, Scottsdale Healthcare, Scottsdale, AZ. Fresh frozentumor biopsy specimens were collected and quality assessed
for tumor cellularity, necrosis, crush artifact, etc. A blood
sample was also provided for the collection of constitu-
tional genomic DNA. RNA and DNA were extracted from
tumor biopsy specimens using the Qiagen All Prep kit
(Qiagen, Germantown, MD). Germline DNA (Table 1)
provides information regarding patients and samples.
Genomic DNA isolation
Fresh frozen tissue
Tissue from the needle biopsy was disrupted and homoge-
nized in Buffer RLT plus, Qiagen AllPrep DNA/RNA Mini
Kit, using the Bullet Blender™, Next Advance. Specifically,
tissue was transferred to a microcentrifuge tube contain-
ing 600 μl of Buffer RLT plus, and stainless steel beads.
The tissue was homogenized in the Bullet Blender at room
temperature. The sample was centrifuged at full speed and
the lysate was transferred to the Qiagen AllPrep DNA
spin column. Genomic DNA purification was conducted
as directed by the AllPrep DNA/RNA Mini Handbook,
Qiagen. DNA was quantified using the Nanodrop spectro-
photometer and quality was accessed from 260/280 and
260/230 absorbance ratios.
Blood
The QIAamp DNA Blood Maxi Kit, Qiagen, was used to
isolate DNA from 8–10 ml of whole blood. The protocol
was conducted as written. Specifically, the buffy coat
layer was isolated from whole blood by centrifugation.
The volume of buffy coat was brought up to 5–10 ml
with PBS and treated with Qiagen protease at 70°C. 100%
ethanol was added and the sample was applied to a
QIAamp Maxi column and centrifuged. Samples were then
washed with buffers AW1 and AW2 and eluted in 1000 μl
of Buffer AE. The Qubit 2.0 Fluorometer, Invitrogen, and
the Nanodrop spectrophotometer, Thermo Scientific, were
used to assess DNA quality and concentration.
Sequencing data analysis
Illumina whole genome sequencing
DNA libraries were prepared using the NEBNext DNA
Sample Prep Master Mix Set (New England Biolabs,
Ipswich, MA). For each sample library preparation, 1 μg
of high molecular weight genomic DNA was fragmented
using the Covaris S2 system. Fragmented samples were
end repaired using T4 DNA polymerase, DNA polymer-
ase I Klenow fragment, and T4 polynucleotide kinase.
Samples were next adenylated using Klenow fragment
3′-5′ exo minus enzyme, ligated with Illumina adapters,
size selected at 350-450 bp, and PCR amplified using
Phusion High-Fidelity PCR Master Mix w/HF buffer
(New England Biolabs). The DNA libraries were clustered
onto flowcells using Illumina’s cBot and HiSeq Paired End
Cluster Generation kits as per manufacturer protocol
Table 1 Patient clinical information
CLN2 CLN3 CLN4
Age at diagnosis 73 45 50
Gender male male male







Tumor cellularity 60% 50% 30%
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samples were carried out using the Illumina HiSeq 2000
platform using the v1.5 chemistry reagents and flowcells.
The CLN4 sample was sequenced on the Illumina HiSeq
2000 platform using the v3 chemistry. The total length of
each paired end sequencing run was 200 cycles.
Single nucleotide variant detection
Somatic single nucleotide variant calling was performed
using SolSNP [18] and Mutation Walker. SolSNP, an
individual sample variant detector (classifier) implemented
in Java does the variant calling based on a modified
Kolmogorov-Smirnov like statistic, which incorporates
base quality scores. The algorithm is non-parametric and
makes no assumptions on the nature of the data. It com-
pares the discrete sampled distribution, the pileup on each
strand, to the expected distributions (according to ploidy).
In case of diploid genome, both strands need to provide
evidence for the variation. Zero quality bases are trimmed
off the pileup before the comparisons. An important aspect
of SolSNP that reduces overcalling inherent to the K-S stat-
istic algorithm is that filters are included to reduce false
positive rates, of which both strands must provide evidence
for the variation.
While making somatic calls, SolSNP’s high quality geno-
type call is made for all callable loci of the normal sample.
To reduce false negatives, variant loci in tumor samples
are called with the Variant Consensus mode. Variant loci
in tumor samples that exhibit a high quality homozygous
reference genotype in the normal sample are considered
as somatic. To call somatic variants, SolSNP is augmented
by a Python script.
Mutation Walker, an in house tool developed in Java,
utilizes the variant discovery tools from Genome Analysis
Toolkit (GATK) [19] as a framework. SNPs that were
called using both tools were compiled and further ex-
amined. Two sets of thresholds, strict and lenient, were
enabled to reduce the false negative rate. Data from
each of these two sets were visually examined for false
positives to generate a final filtered list of true SNVs,
which were annotated with GENCODE using an in-
ternal annotation script.Copy number analysis
For copy number analysis, a custom tool was developed
based on a sliding window comparison of coverage for
tumor/normal. This method has been adopted by Liang
et al. for their analysis [16]. Copy number gains and losses
were calculated from log2 difference in normalized physical
coverage between germline and tumor samples across a
sliding window of 2 kb, where physical coverage was
incremented for the length of the insert between the
read pairs for insert sizes less than 3 standard deviations
of the mean. High repeat regions such as centromeres were
defined as regions where the log2 normalized coverage
exceeded 3 in the germline sample and were thus excluded.
Regions where the coverage was zero were replaced by 1 so
that homozygous deletions avoid infinite values and are
generally capped at approximately −3.
Indel (Insertion/deletion) detection
For detecting somatic indels we employed a two-step strat-
egy. In the first step we removed from the tumor sample
bam, reads whose insert size lay outside a 50 bp - 500 bp
interval from the tumor bam files. GATK [19] is then used
to generate a list of potential small indels from this bam. A
customized perl script, which uses the Bio-SamTools library
from BioPerl [20], takes these indel positions and for each
of the indels looks at the region in the normal sample con-
sisting of 5 bp upstream from the start and 5 bp down-
stream from the end of the indel. An indel is determined to
be somatic only if there was no indel detected in the region
under consideration in the normal DNA.
Translocation detection
A series of customized perl scripts are employed in the
detection of translocation. These scripts use SAMtools [21]
internally to access the bam files. The algorithm consists of
two steps. The first is to detect potential translocation in
both tumor and normal samples. The second is a compari-
son of potential translocations in tumor to those detected
in the normal sample to weed out potential false positives.
The detection of a potential translocation is an exercise in
outlier detection. We take a sliding window of 2kbp and
count the discordant reads, whose mates align on a differ-
ent chromosome. We use 2kbp, as it is close to the mean
of the estimated insert size distribution, and gives the best
resolution for the detection of an interchromosomal trans-
location. For each window we choose the highest hit to be
the chromosome to which mates of most of the discordant
reads mapped. For purposes of brevity, we call the subset of
discordant reads whose mate maps to the highest hit in the
window as the hit discordant reads. We compare the ratios
of the hit discordant reads, to the total aligned reads, across
all the windows to detect potential outliers. Outlier de-
tection is performed under the assumption that the
distribution, of the proportion of hit discordant reads
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and will follow a normal distribution. We then compute
the mean of this distribution and choose a cutoff of 3
standard deviations. The window with a proportion of
hit discordant reads, higher than this cutoff contains
the region of potential translocation. The actual region
of translocation is then determined by the span of the
hit discordant reads in the window. For somatic trans-
locations, the normal and the tumor sample are called
separately and regions of overlap are eliminated. These
regions were further inspected visually to reduce false
positives to arrive at the most confident list.
SIFT analysis
Single nucleotide variations identified from paired tumor
normal analysis were analyzed using the SIFT algorithm.
Non-synonymous SNPs in the coding region were checked
to see if an amino acid substitution in the protein
could actually be damaging by altering the function of
the protein [22].
Cell culture conditions and treatments
X-MAN HCT116 cell line was purchased from Horizon
Discovery Ltd. (Cambridge, UK) and cultured in McCoy’s
5A modified media with 10% FBS (Life Technologies,
Grand Island, NY). HEK293 cells were obtained from
the American Type Culture Collection (ATCC) and
passaged in RPMI with 10% FBS and 100 units insulin
(Sigma-Aldrich, St. Louis, MO). Inhibition of INPPL1
expression was achieved through the use of siRNA se-
quences (Qiagen, Valencia, CA). siRNA transfections were
performed with Lipofectamine 2000 (Life Technologies)
and pooled INPPL1 (FlexiTube GeneSolution GS3636)
siRNA sequences [Qiagen]. Non-silencing negative con-
trol and GFP siRNA sequences were utilized as negative
controls (Qiagen). AllStars Hs Cell Death and UBBs1
sequences served as positive controls to assess transfection
efficiency (Qiagen). Cells were seeded in 384-well pates
containing siRNA sequences (i.e., reverse transfection) and
proliferation was measured via CyQUANT Direct Cell
Proliferation Assay (Life Technologies). Changes in pro-
liferation were assessed based on comparison of non-
silencing siRNA controls to target siRNA. Data shown
for siRNA experiments was generated using Excel version
14.3.5 (Microsoft Corporation, Redmond, WA). For siRNA
data, differences in proliferation were evaluated by T Test
and p values ≤ 0.05 were considered statistically significant.
Cell lysates and immunoblotting
Untreated as well as transfected whole cell lysates were
prepared using the cOmplete Lysis-M kit (Roche Applied
Science, Indianapolis, IN). Protein samples were prepared
by combining lysates with NuPAGE Sample Reducing
Agent, NuPAGE LDS Sample Buffer, and nuclease-freewater (Life Technologies) and then boiling for 5 minutes at
100°C. Samples were loaded onto NuPAGE 4-12% Bis Tris
Gels (Life Technologies), separated by SDS-PAGE, and then
transferred to PVDF membranes. Proteins were blocked in
5% non-fat milk and incubated with the appropriate anti-
body in 5% BSA (Sigma-Aldrich). The following antibodies
were used for Western blot analyses: AKT (#9272), pAKT
Thr308 (#4056), pAKT Ser473 (#4058), CASP7 (#9492),
Fox01 (#2880), pFox01 Ser256 (#9461), GSK-3β (#9315),
pGSK-3β Ser9 (#9336), INNPL1 (#2839), p70 S6 Kinase
(#2708), PDK1 (#5662), pPDK1 Ser241 (#3438), PI3K
p85 (#4292), and GAPDH (#2118) [Cell Signaling,
Danvers MA]; and pGSK-3β Tyr216 (#75745) [Abcam
Inc., Cambridge, MA]. Protein bands were visualized
using Pierce ECL Western Blotting Substrate (Thermo
Fisher Scientific, Rockford, IL).
Results
Clinical history
Four patients were recruited for this study. In patient
CLN1, the tumor sample was not considered adequate
for NGS and results are not presented. Clinical information
is provided in Table 1.
Patient CLN2 is a 73 year old Caucasian male first diag-
nosed with a T3N2 moderately differentiated adenocarcin-
oma of the ascending colon. He received adjuvant therapy
with FOLFOX but had rapid recurrence of disease 5 months
after initial surgery. The patient had subsequent therapy
with irinotecan/bevacizumab and then gemcitabine, mito-
mycin and insulin potentiating therapy. At time of referral,
there was metastatic disease in the pelvis and multiple
omental lesions. A CT guided biopsy of a nodule in the
right side of the abdomen was performed. The biopsy
from this mass (60% tumor cellularity) was consistent with
the colon primary.
Patient CLN3 is a 45 year old Caucasian male first di-
agnosed with a T2NO rectal cancer for which primary
surgery was performed. The patient was found to have
recurrent lung metastasis and a pelvic pre sacral mass
18 months after surgery. He also had a chronic draining
fistula in the right buttock which developed soon after
surgery. A hard mass developed in the right buttock and
on biopsy was found to be another site of metastasis.
Treatment for metastatic disease had included FOLFOX
/bevacizumab, lung radiation and isolated pelvic chemo-
therapy perfusion. A biopsy of the right buttock mass
was performed with pathology consistent with the rectal
primary (50% tumor cellularity).
Patient CLN4 is a 50 year old Hispanic male diagnosed
with hemicolectomy for a T3N1 right sided colon cancer.
The patient was found to have synchronous liver metasta-
sis at the same time. He had undergone prior therapy with
FOLFOX, FOLFIRI/bevacizumab and yittum-90 therapy
to the liver. The patient entered the study 3 years after
Shanmugam et al. BMC Medical Genomics 2014, 7:36 Page 5 of 13
http://www.biomedcentral.com/1755-8794/7/36first diagnosis of metastatic disease and had tumors in the
liver and a soft tissue mass in the epigastric area of the ab-
domen. A biopsy from the abdominal mass was consistent
with the colon primary (30% tumor cellularity).
Whole genome sequencing
For each patient tumor and germline DNA were se-
quenced to identify somatic alterations. WGS summary
statistics are shown in Table 2. Aligned reads from both
tumor and normal samples were evaluated for somatic
events including non-synonymous single nucleotide vari-
ants (nsSNVs), indels, copy number variants (CNVs) and
translocations. Circos plots in Additional files 1, 2 and 3
illustrate somatic events occurring in CLN2, CLN3 and
CLN4 respectively [23].
The complete lists of somatic SNVs detected in the
three evaluable specimens are provided in Additional file
4: SNVs and Indels. All three tumors contained KRAS
mutations. Among the cancer genes mutated in patient
CLN2 were APC, KRAS, PIK3CA, SMAD4,MYST4, HUNK,
INPPL1, TGFβ3, and TCF7L2. Cancer genes mutated in
CLN3 included KRAS, INPP4B, PTPRE, CARD16 and
LRP2. Cancer gene mutations in CLN4 were detected in
APC, KRAS, PIK3CA, KDR and AURKC (Table 3). Some of
the genes which were known to have non-synonymous mu-
tations in colon cancer genes in prior studies were also seen
in these samples. They include APC, KCNQ5, KIAA1409,
KRAS, LRP2, PIK3CA, SMAD4,TCF7L2 and UHRF2 [9].
Non-synonymous SNVs found in the coding regions of
genes were analyzed using the SIFT (Sorting Tolerant From
Intolerant) algorithm to determine if such mutations
may affect protein function [22]. Genes identified to have
damaging effects on the protein product are indicated in
Additional file 5: SIFT Predictions for SNVs and Indels.
Of the 115 coding variants in CLN2, 61 were predicted to
be damaging (53%); CLN3 had 90 coding variants of which
38 were damaging (42%); and CLN4 had 44 coding variants
of which 20 were damaging (47%).
Copy number analysis
Copy number analysis was performed using a sliding
window comparison of coverage between tumor and
normal using our in-house custom tool. Regions of gainTable 2 Whole genome sequencing





CLN2 Normal 1.9 billion 200 Gb 50X
CLN2 Tumor 1.4 billion 146 Gb 42X
CLN3 Normal 2.0 billion 210 Gb 62X
CLN3 Tumor 1.96 billion 204 Gb 40X
CLN4 Normal 0.97 billion 100 Gb 28X
CLN4 Tumor 1.03 billion 107 Gb 31Xor loss in the tumor samples are outputted as log2 ratios
in Additional file 6: CNVs. CLN2 had whole chromosome
copy number gain of chromosome 13, and chromosome
8q. Significant genes deleted in CLN2 include TP53,
BCL2, PIK3CA, SMAD2, SMAD3, SMAD4, APC2, DCC,
TGFβ1, TCF3, TCF4 and TCF12. CLN3 exhibited whole
chromosome copy number gain of chromosomes 1 – 5. A
significant amplification occurred at 1pter and encompassed
NOCL2, PLEKHN1, SDF4, UBE2J2, CENTB5, CPSF3L,
MXRA8, ATAD3B, ATAD3A, SSU7A, SLC35E2, NADK,
GNB1, GABRD, and PRKCZ. A focal amplicon at 12p con-
tains KRAS, which is also mutated in this patient’s tumor.
An interstitial deletion of about 16 Mb was seen in chromo-
some 13, which encompasses the RB1 locus. Somatic copy
number analysis in CLN4 was confounded by low tumor cel-
lularity (30%); however we were able to detect several events
including whole chromosome gain of chromosome 13.
Furthermore, several genes containing SNVs also mapped
within regions of copy number change. A list of these
genes has been included in Table 4. Notably in CLN2,
SMAD4 was deleted and harbored an L540R somatic
mutation. Additionally, PTPRM was deleted and contained
aV1415M nsSNV.
Impact of INPPL1 silencing on cell proliferation in
HCT116 cells
The PI3 kinase pathway has been previously associ-
ated with colorectal cancer, where PIK3CA mutations
occur in approximately 15% of colorectal tumors [10,24].
Phosphatidyl-3,4,5-triphosphate (PI3,4,5P3), is a key phos-
phoinositide generated from PI3 kinase, which regulates
PKB/AKT mediated cell survival and proliferation [25].
In our analysis, we identified a mutation in INPPL1
(inositol polyphosphate phosphatase-like 1), which en-
codes SHIP2, the phosphatase that plays an important role
in the conversion of PI3,4,5P3 to PI3,4P2. The E567G muta-
tion identified in the INPPL1gene was predicted to be dam-
aging by SIFT, and validated by Sanger sequencing. Thus we
investigated the impact of silencing INPPL1 by RNA inhib-
ition on cell proliferation. For this study, we used small
interfering RNA (siRNA). HCT116 cells were seeded into
384-well plates containing siRNA buffer (no transfection),




2.3 million 88% 2.05
—
3.4 million 88% 2.06
—
3.3 million 88% 2.06
—
Table 3 SNVs and indels in relevance to cancer
Sample Chr Gene name Position Coding event Sequence change Substitution
CLN2 3 CPB1 150045158 SNV G/A R231Q
6 ESR1 152423875 SNV C/T T431I
10 TCF7L2 114907771 SNV G/A G424E
11 INPPL1 71621016 SNV A/G E567G
12 KRAS 25289548 SNV C/T G13D
14 TGFβ3 75495381 SNV G/T Q381K
18 BCL2 59136317 SNV C/A W188L
18 PTPRM 8384547 SNV G/A V1415M
10 MYST4 76460457 SNV C/T R1957W
18 SMAD4 46858795 SNV T/G L540R
19 SHANK1 55864301 SNV G/A R910C
21 HUNK 32293208 SNV G/A R662Q
3 PIK3CA 180399422 SNV G/A NA
1 PTPRC 196985273 SNV G/A S852N
13 MLNR 48693327 Indel cccgg−/−ccgcc Insertion
2 SLC4A10 162427730 Indel atcag−/−aaaa Insertion
6 UTRN 145111149 Indel AAAT-g-GGAAA Frameshift
7 HNRNPA2B1 26202550 Indel CAGAT-cctcc-TCTAA Frameshift
CLN3 1 ARID1A 26973896 SNV G/T E1531
2 LRP2 169845248 SNV T/C N400S
3 MITF 70011193 SNV C/G S92C
4 INPP4B 143222686 SNV C/A E864
5 GPR98 89974441 SNV G/T V787L
7 CYLN2 73409559 SNV C/A S344Y
10 PTPRE 129758044 SNV G/A R369Q
12 KRAS 25289551 SNV C/T G12D
4 MAML3 26202550 Indel AAAT-ctg-CTGCT AA_Deletion
6 PGC 140871034 Indel CCTGC-aga-AGAGC AA_Deletion
CLN4 1 ARID4B 233412380 SNV C/A R826M
3 PIK3CA 180434779 SNV A/G H1048R
4 KDR 55655861 SNV G/A R946C
5 APC 112129944 SNV G/T G53V
5 APC 112201150 SNV C/T Q654
5 APC 112203580 SNV G/T E1464
5 APC 112205360 SNV A/G K2057R
6 PTCRA 42998820 SNV G/T V46F
12 KRAS 25289552 SNV C/A G12C
2 HOXD9 176696536 Indel cagcc-/gcagc Insertion
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Changes were measured based on differences between
non-silencing control siRNA and INPPL1 siRNA sequences
(Figure 1). At 72 hours post-transfection, we detected a
65% decrease in HCT116 cell proliferation, suggesting that
INPPL1may be required for CRC cell growth.Impact of INPPL1 siRNA on protein expression of
downstream signaling targets of PI3K -Western analysis
Since SHIP2 plays a role in PI3K/AKT signaling, INPPL1
siRNA transfected and untransfected HCT116 cell lysates
were used for Western blots and probed with anti-
bodies to several downstream PI3K/AKT pathway targets
Table 4 Correlation of genes with SNVs and amplifications and deletions
Sample Chr Gene name SNV location CNV variant type Change associated with variant Start End Correlation
CLN2 8 ADAMDEC1 24312932 CNV-Loss -1.098323504 24298000 24318700 -
18 BCL2 59136317 CNV-Loss -1.142019005 58946900 59136800 -
17 C17orf39 17905985 CNV-Loss -1.086327397 17886900 17909200 -
13 DNAJC3 95127539 CNV-Gain 1.034261883 95159600 95201700 +
18 DOK6 65495961 CNV-Loss -1.080170349 65220300 65659400 -
19 EEF2 3929160 CNV-Loss -1.10433666 3927700 3935600 -
13 MED4 47567121 CNV-gain 1.011225847 47549300 47562800 +
15 MORF4L1 76965549 CNV-Loss -1.25642835 76953100 76976400 -
19 OR1M1 9065467 CNV-Loss -1.185833041 9065000 9065800 -
13 PCDH17 57105203 CNV-Gain 1.158413612 57105000 57140500 +
8 PI15 75900191 CNV-Gain 1.077222314 75901700 75924000 +
15 PML 72124335 CNV-Loss -1.130706684 72074500 72122000 -
18 PTPRM 8384547 CNV-Loss -1.028666588 7637600 8387100 -
19 PVRL2 50083243 CNV-Loss -1.070323897 50042300 50073700 -
19 SHANK1 55864301 CNV-Loss -1.135111902 55859100 55907600 -
18 SMAD4 46858795 CNV-Loss -1.077097357 46827500 46855600 -
15 THSD4 69844560 CNV-Loss -1.12539172 69808500 69856700 -
8 VPS13B 100723477 CNV-Gain 1.06690452 100098000 100957000 +
19 XAB2 7594144 CNV-Loss -1.039001256 7596500 7599800 -
19 ZNF235 49483380 CNV-Loss -1.210566986 49486200 49499300 -
19 ZNF480 57510937 CNV-Loss -1.12807401 57496100 57517900 -
19 ZNF83 57808787 CNV-Loss -1.330073623 57808100 57809600 -
CLN3 4 ANKRD17 74175875 CNV-Gain 1.050578956 74176700 74257700 +
2 APOB 21086873 CNV-Gain 1.381146277 21078200 21119700 +
1 ARID1A 26973896 CNV-Gain 1.088551435 26707600 26977900 +
3 ATP13A5 194544518 CNV-Gain 1.074832063 194495900 194576400 +
2 CLEC4F 70897420 CNV-Gain 1.474467603 70890000 70900800 +
1 FNDC7 109063011 CNV-Gain 1.060116535 109071800 109085900 +
3 GADL1 30871204 CNV-Gain 1.083837201 30750200 30822400 +
4 GUCY1A3 156862650 CNV-Gain 1.051035883 156845700 156866700 +
4 INPP4B 143222686 CNV-Gain 1.071823665 143169400 143560600 +
2 IWS1 127960697 CNV-Gain 1.157172502 127955100 127999800 +
3 KCNMB2 180028679 CNV-Gain 1.036705549 180021600 180027700 +
12 KRAS 25289551 CNV-Gain 1.035184393 25274800 25275900 +
2 LRP2 169845248 CNV-Gain 1.274350136 169693500 169926300 +
3 LSG1 195872054 CNV-Gain 1.046959963 195844100 195855800 +
1 MACF1 39573148 CNV-Gain 1.075279401 39322700 39722600 +
3 MITF 70011193 CNV-Gain 1.055910933 70070200 70096500 +
5 PAPD4 78951267 CNV-Gain 1.023426699 78969500 78969700 +
2 PCBP1 70168678 CNV-Gain 1.147337373 70169200 70169400 +
4 PDE5A 120666238 CNV-Gain 1.066043219 120655300 120742100 +
1 PHTF1 114082912 CNV-Gain 1.075512922 114060600 114098600 +
3 RPSA 39428561 CNV-Gain 1.099952073 39424200 39428600 +
4 SH3BP2 2805228 CNV-Gain 1.208480128 2792500 2804000 +
Shanmugam et al. BMC Medical Genomics 2014, 7:36 Page 7 of 13
http://www.biomedcentral.com/1755-8794/7/36
Table 4 Correlation of genes with SNVs and amplifications and deletions (Continued)
5 SLC6A19 1265596 CNV-Gain 1.142273516 1257300 1274700 +
3 SMC4 161633513 CNV-Gain 1.02766824 161602500 161603100 +
2 SMYD5 73305580 CNV-Gain 1.59092836 73301300 73306500 +
1 SPOCD1 32038250 CNV-Gain 1.187067318 32029900 32040400 +
1 ST6GALNAC3 76650550 CNV-Gain 1.08116566 76355200 76864700 +
1 TMEM39B 32340671 CNV-Gain 1.071050645 32318800 32339600 +
2 VPS54 63993297 CNV-Gain 1.158423232 63974100 64064600 +
2 WDR35 20045755 CNV-Gain 1.180181947 19976800 20052800 +
5 WWC1 167824543 CNV-Gain 1.083413977 167656200 167825900 +
CLN4 16 ABCC12 46688204 CNV-Gain 0.757287 46702800 46702800 +































Figure 1 Effect of INPPL1 siRNA on cell proliferation in HCT116 cells. Changes in proliferation in HCT116 cells 72 hours post-transfection with
pooled control or pooled INPPL1 sequences. Fluorescence data is shown for cells only (no siRNA sequences), negative controls (non-silencing
siRNA sequences), INPPL1 siRNA, and positive controls (siRNA sequences targeting essential genes). The effects of INPPL1 siRNA are based on
differences between average fluorescence signal generated by negative controls and INPPL1 siRNA sequences. Asterisks denotes statistical significance.
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http://www.biomedcentral.com/1755-8794/7/36as illustrated in Figure 2. HEK293 cell lysates were used
as a positive control in our western blots, due to the
ease of maintenance, abundance of proteins, and known
expression of multiple proteins. As expected, a reduction in
INPPL1 protein levels was observed at 24, 48 and 72 hours
post transfection. INPPL1 siRNA treated HCT116 cells
showed no expression of PI3K as early as 24 hours post
transfection. Hence we looked at the protein levels of a
series of downstream signaling targets of PI3K. For PDK1,
both pPDK1 (Ser 241) and PDK1 antibodies were used.
In the untransfected cell lines, pPDK and PDK1 were
expressed. Similar to PI3K, INPPL1 siRNA treated cells
showed no expression of either the pPDK1 or PDK1 at
24 and 48 hours. AKT phosphorylation was detected at
T308 and S473 in HEK293 cells, however, only phosphor-
T308 was detected in HCT116 cells. Total AKT was
detected at high levels in HCT116 cells. INPPL1 siRNA
transfected cells showed a marked reduction in the
phosphorylation of AKT as seen in 24 and 48 hours post
transfection. Moreover, INPPL1 siRNA inhibited total AKT
protein expression at 48 hours in HCT116 cells, with ex-
pression returning at 72 hours post transfection. INPPL1
siRNA transfection also led to reduced p70 S6 kinase in the
HCT116 cells within 24 hours post transfection. Phosphor-
ylated FOX01 (Ser256) was detected in untransfected cells,
but was significantly diminished in HCT116 cells trans-
fected with INPPL1 siRNA. Another downstream effectorFigure 2 Western blots. Basal protein expression of HEK293 and HCT116
72 hours post-INPPL1 siRNA transfection. For post-transfection samples, cel
harvested at each time point.of AKT is GSK-3β, which upon phosphorylation by AKT at
Ser9 becomes inactivated leading to increased cell cycle
and β-catenin signaling. INPPL1 siRNA led to decreased
total GSK-3β at 24 hours in HCT116 parental cell lines.
Interestingly, INPPL1 knockdown in HCT116 cells led
to increased phospho-(Ser9) GSK-3β in HCT116 cells at
48 hours. Finally, Caspase 7 activation, which is an indica-
tor of apoptosis, also increased as indicated by the cleaved
35 kDa band in INPPL1 siRNA transfected HCT116
cells. These results support inactivation of the PI3K/AKT
pathway upon INPPL1 knockdown, suggesting a growth
promoting role for INPPL1 in colon cancer.
Discussion
It is now established that the key mediators of the cancer
cell phenotype are single base mutations, copy number
alterations, translocations/rearrangements and epigenetic
modifications of genomic DNA. Only now with the advent
of NGS and bioinformatics capabilities can the entire
human genome be interrogated for these changes. Import-
antly, with the development of targeted therapies, somatic
genome analysis of tumors can shed light on possible thera-
peutically relevant events that might help inform treatment
recommendations for advanced cancers.
In our small sample size, all three tumors had mutations
in KRAS. KRAS mutations have been observed in 33%
of the CRCs and are crucial for the early progression ofcells as well as changes in expression in HCT116 cells 24, 48, and
l lysates were treated with pooled INPPL1 siRNA sequences and
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KRAS mutations in CRC tumor samples are an early
event in the progression of colon carcinoma and the
only predictive molecular marker useful for treatment
decision as EGFR directed therapy is ineffective in the
context of concomitant KRAS mutation [26]. However,
even in the presence of KRAS wild type, therapy with
either cetuximab or panitumumab is only effective in
about 30% of cases suggesting that there are other mo-
lecular determinants of resistance. Additional genes
harboring somatic mutations that have been character-
ized as cancer genes in our study include, APC, TGFβ3,
SMAD4, BCL2, INPPL1, INPP4B, PIK3CA, PTPRE and
KDR. Mutations in the APC gene have been identified
in sporadic cancers and play a role in the WNT/β-catenin
signaling pathway. Loss of APC function leads to β-catenin
accumulation and binding to TCF/LEF transcription factors
thereby activating MYC and cyclin D1 leading to the trans-
formation of the colon epithelium [27]. Thus APC muta-
tions generally play a role in the initiation of colorectal
cancers. APC also regulates cell proliferation of RAS in-
duced ERK activation playing an important role in colorec-
tal tumor suppression [28]. Colorectal tumors are known
to have mismatch repair mutations that can increase the
mutation rate in these tumors. However, one cannot also
rule out the possibility that some of the mutations identi-
fied in these advanced cancers are not the result of previ-
ously administered chemo or radiation therapies.
Some notable CNVs were seen in these patients. CLN2
had amplification in the MYC oncogene. A number of
known tumor suppressor genes were deleted in CLN2
such as TP53, SMAD2, SMAD3, SMAD4, BCL2 and
TCF4. SMAD4 alterations occur in over 50% of CRC
and are believed to occur later in the course of disease [29].
SMAD4 acts as a tumor suppressor to inhibit β-catenin
[30] and targets the TGFβ signaling pathway to control
epithelial cell growth [31]. Tumor CLN2 contained SMAD4
deletion and a concomitant SMAD4 mutation. Deletion
of BCL2 leads to an increase in the relapse of stage II
colon cancers and could be a likely biomarker for thera-
peutic decisions [32]. Importantly, CLN2 also contained
a somatic mutation in the BCL2 gene. TCF4 has been
found to be mutated in variety of tumor types such as
renal cell carcinoma, gastric carcinoma and breast cancer
[33,34]. TCF4 mutations have been reported in primary
CRCs and its loss induces cell proliferation suggesting
a possible role as a tumor suppressor [35-37]. CLN3 has a
copy number gain encompassing the VEGFA locus, found
in 3% of the cases and linked to higher tumor grade and
vascular invasion and being an aggressive subgroup [38].
Copy number gain was also noted in KDR (VEGFR-2),
a mediator of angiogenesis and its expression correlated
with poor outcome in non-small cell lung carcinoma
[39-42]. CLN4 had amplification of EGFR, CDK8, andMIRH1. EGFR mutations in the extracellular domain with
gene amplifications are common in glioblastomas [43] and
mutations in the tyrosine kinase domain with increased
copy numbers are seen in lung carcinomas. However, amp-
lification of EGFR seems to be an uncommon event in colo-
rectal cancer [44,45]. CDK8, a cyclin dependent kinase
amplified in CLN4, plays a major role in cell proliferation
and PI3K inhibitors can be used in clinical trials for CDK8
[46]. With regards to structural events in colon cancer, gene
fusions of TCF7L2 with VTI1A have previously been ob-
served in 3% of the colon cancers [11]. We did not detect
this translocation event in any of our tumors due to our
sample size, however we did detected a novel TCF7L2
(G424E) mutation in one of our tumors, suggesting that
this gene can be perturbed by multiple mechanisms.
In our three CRC cases that underwent successful NGS,
mutations were detected in genes and pathways that could
possibly be therapeutically targetable. The PI3K pathway
is recognized to be critical in cellular transformation, cell
proliferation, adhesion, survival, and motility of cancer cells.
In support of our observations, studies have shown that
PIK3CA is mutated in up to 30% of CRC as well as other
tumors such as breast, ovarian, and liver cancer [47] typic-
ally leading to activation of the PI3K/AKT/mTOR signaling
pathway. Activated PI3K leads to an increase in the phos-
phoinositides PI3,4,5P3 and PI3,4P2 which in turn leads to
phosphorylation of AKT. PI3,4,5P3 serves as a substrate for
SHIP2 where it is converted to PI3,4P2. Both PI3,4,5P3 and
PI3,4P2 have been shown to activate AKT phosphorylation
[48]. However studies have shown that PI3,4P2 is more effi-
cient than PI3,4,5P3 in binding to the PH domain of AKT,
phosphorylating S473 and leading to membrane activation
[25,49]. In vitro studies using phospholipid vesicles with
PI3,4P2 alone were sufficient to activate AKT [50]. INPPL1,
encodes SHIP2, the inositol phosphatase that converts
PI3,4,5P3 to PI3,4P2. SHIP2 is also a negative regulator of
insulin signaling, plays an important role in EGF receptor
turnover, and also has been reported to negatively regulate
the PI3K pathway [51]. INPPL1 has been shown to act
as either a tumor suppressor or an oncogene in different
tumor types. Furthermore, SHIP2 expression has been
associated with metastasis in breast cancer [52]. INPPL1
mutations have been previously reported and occur in ~4%
of colon tumors [53]. The INPPL1 E567G mutation discov-
ered in tumor CLN2 resides within the catalytic inositol
polyphosphate 5-phosphatase domain that is critical to in-
ositol phosphatase activity, and is predicted to be damaging
by SIFT. Thus we performed additional functional genomic
and mechanistic studies using RNAi to better understand
the role of INPPL1 in colon cancer cell growth and sig-
naling. We used the HCT116 cell line model, which also
harbors PIK3CA and KRAS mutations, similar to the pa-
tient containing the INPPL1 mutation. As knockdown
of INPPL1 led to growth suppression, we hypothesize
Shanmugam et al. BMC Medical Genomics 2014, 7:36 Page 11 of 13
http://www.biomedcentral.com/1755-8794/7/36that this mutation may lead to a gain of function of INPPL1
thereby playing an oncogenic role in colon cancer as indi-
cated by our in vitro studies. Upon INPPL1 knockdown, we
observed significant negative changes in phopho-signaling
of key effectors of the PI3K/AKT pathway that suggest
INPPL1 might promote growth in colon cancer. This is an
important insight as SHIP2 converts PI3,4,5P3 to PI3,4P2,
which has been shown to directly activate AKT independ-
ent of PI3,4,5P3. Studies by Fuhler et al. also show that
treatment of multiple myeloma cells with SHIP1/2 inhibi-
tors causes cell arrest in the G2/M phase and induction of
apoptosis via Caspase activation [54]. Therefore, additional
studies of the role of SHIP2 in CRC are warranted, as
this could provide alternative ways to approach inhib-
ition of the PI3K/AKT axis as a means of treatment for
a subset of colon cancer tumors.Conclusion
This study provides insights into the mutational landscape
of metastatic recurrent colorectal cancer. KRAS being the
most frequently mutated in human cancers with ~30% in
colorectal cancers are the hallmarks in all these tumor
samples. Several inhibitors for the downstream signaling
targets of RAS such as RAF and MEK have not been very
successful. PI3K inhibitors have been used in phase II
clinical trials but have also not been very promising.
There remains an urgent need to develop KRAS inhibitors
to enhance treatment options in mCRC patients with KRAS
mutations. Using an in vitro model with a colon cancer cell
line, we have identified that an effective way of activating
AKT signaling could be through PI3,4P2 and INPPL1. The
inhibition of INPPL1 may have a very significant role in cell
proliferation and survival in colon cancer. And although
specific recurrent mutations exist, our study further high-
lights therapeutically relevant contexts within metastatic
colon tumors that might lead to new and improved ways to
manage these difficult to treat tumors.Additional files
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